NYSE:MNK

Mallinckrodt Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$0.20
0.00 (0.00 %)
(As of 09/23/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.19
$0.20
50-Day Range
$0.14
$0.75
52-Week Range
$0.75
$6.42
Volume177,784 shs
Average Volume6.49 million shs
Market Capitalization$16.54 million
P/E RatioN/A
Dividend YieldN/A
Beta3.06

Receive MNK News and Ratings via Email

Sign-up to receive the latest news and ratings for Mallinckrodt and its competitors with MarketBeat's FREE daily newsletter.


Mallinckrodt logo

About Mallinckrodt

Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.71 out of 5 stars

Medical Sector

866th out of 1,351 stocks

Pharmaceutical Preparations Industry

425th out of 664 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Mallinckrodt (NYSE:MNK) Frequently Asked Questions

What stocks does MarketBeat like better than Mallinckrodt?

Wall Street analysts have given Mallinckrodt a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Mallinckrodt wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Mallinckrodt's earnings last quarter?

Mallinckrodt plc (NYSE:MNK) posted its quarterly earnings results on Tuesday, August, 4th. The company reported $1.89 EPS for the quarter, topping analysts' consensus estimates of $1.34 by $0.55. The company earned $700.90 million during the quarter, compared to analysts' expectations of $630.19 million. Mallinckrodt had a positive trailing twelve-month return on equity of 34.26% and a negative net margin of 89.94%. Mallinckrodt's revenue was down 14.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.53 EPS.
View Mallinckrodt's earnings history
.

Who are Mallinckrodt's key executives?

Mallinckrodt's management team includes the following people:
  • Mark C. Trudeau, President, Chief Executive Officer & Director
  • Bryan M. Reasons, Chief Financial Officer & Executive Vice President
  • Steven Joseph Romano, Chief Scientific Officer & Executive VP
  • Babatunde Adekunle Otulana, Chief Medical Officer & Senior Vice President
  • Michele Robertson, Chief Compliance Officer & Senior Vice President

What other stocks do shareholders of Mallinckrodt own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mallinckrodt investors own include Gilead Sciences (GILD), Micron Technology (MU), Bausch Health Companies (BHC), Endo International (ENDP), Teva Pharmaceutical Industries (TEVA), Gerdau (GGB), AT&T (T), Alibaba Group (BABA), (CELG) and Advanced Micro Devices (AMD).

What is Mallinckrodt's stock symbol?

Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."

What is Mallinckrodt's stock price today?

One share of MNK stock can currently be purchased for approximately $0.20.

How much money does Mallinckrodt make?

Mallinckrodt has a market capitalization of $16.54 million and generates $3.16 billion in revenue each year. The company earns $-996,500,000.00 in net income (profit) each year or $8.88 on an earnings per share basis.

How many employees does Mallinckrodt have?

Mallinckrodt employs 3,400 workers across the globe.

What is Mallinckrodt's official website?

The official website for Mallinckrodt is www.mallinckrodt.com.

Where are Mallinckrodt's headquarters?

How can I contact Mallinckrodt?

Mallinckrodt's mailing address is COLLEGE BUSINESS & TECHNOLOGY PARK CRUISERATH BLANCHARDSTOWN, DUBLIN 15 L2, D15. The company can be reached via phone at (531) 696-0000 or via email at [email protected].


This page was last updated on 9/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.